CoChat

Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example

Open access
Aroda, Vanita R., Saugstrup, Trine, Buse, John B., Donsmark, Morten, Zacho, Jeppe, Davies, Melanie J. · 2019 · Diabetes, Obesity and Metabolism
Cited by 69

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Regulatory guidelines describe the use of estimands in designing and conducting clinical trials. Estimands ensure alignment of the objectives with the design, conduct and analysis of a trial. An estimand is defined by four inter‐related attributes: the population of interest, the variable (endpoint) of interest, the way intercurrent events are handled and the population level summary. A trial may employ multiple estimands to evaluate treatment effects from different perspectives in order to address different scientific questions. As estimands may be an unfamiliar concept for many clinicians treating diabetes, this paper reviews the estimand concept and uses the PIONEER 1 phase 3a clinical trial, which investigated the efficacy and safety of oral semaglutide vs placebo, as an example of the way in which estimands can be implemented and interpreted. In the PIONEER 1 trial, two estimands were employed for each efficacy endpoint and were labelled as: (a) the treatment policy estimand, used to assess the treatment effect regardless of use of rescue medication or discontinuation of trial product, and provides a broad perspective of the treatment effect in the population of patients with type 2 diabetes in clinical practice; and (b) the trial product estimand, used to assess the treatment effect if all patients had continued to use trial product for the planned duration of the trial without rescue medication, thereby providing information on the anticipated treatment effect of the medication. Both approaches are complementary to understanding the effect of the studied treatments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.13804

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 15

  1. National Research Council, 2010, The Prevention and Treatment of Missing Data in Clinical Trials. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of Behavioral and Social Sciences and Education
  2. 10.1002/pst.1705 · DOI
  3. 10.1002/pst.1817 · DOI
  4. 10.1001/jama.2019.2942 · DOI · Paper page
  5. 10.1080/19466315.2017.1302358 · DOI
  6. 10.1002/cpt.872 · DOI
  7. 10.1002/sim.6840 · DOI
  8. 10.1002/pst.1536 · DOI
  9. 10.1002/pst.1765 · DOI
  10. 10.1002/sim.6841 · doi:10.1002/sim.6841
  11. 10.1177/1740774516633115 · DOI
  12. Little RJA, 1987, Statistical Analysis with Missing Data
  13. Novo Nordisk, OZEMPIC® (semaglutide injection) Prescribing Information
  14. 10.1016/S2213-8587(17)30085-2 · DOI · Paper page
  15. 10.1016/j.diabet.2018.09.002 · DOI · Paper page

Cited by

See all 69

Metadata

Authors
Aroda, V. R., Saugstrup, T., Buse, J. B., Donsmark, M., Zacho, J., & Davies, M. J.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2019-06-30
Volume
21
Issue
10
Pages
2203-2210
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2953860251
Cited by
69
References
2
FWCI
9.68
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example. https://app.cochat.ai/papers/10.1111/dom.13804
The paper
Aroda, V. R., Saugstrup, T., Buse, J. B., Donsmark, M., Zacho, J., & Davies, M. J. (2019). Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13804

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.